The risk of death, hospitalization and serious health issues from COVID-19 jumps significantly with reinfection compared with a first bout with the virus, regardless of vaccination status, a study published on Thursday suggests.

U.S. President Joe Biden said in an interview aired on Sunday that “the pandemic is over,” even though the country continues to grapple with coronavirus infections that kill hundreds of Americans daily.

In a recent large-scale study, Pfizer’s Paxlovid (nirmatrelvir and ritonavir tablets) appeared to be far more effective at reducing deaths and hospitalizations in older adults than younger patients stricken with the Omicron variant of COVID-19.

UnitedHealth Group Inc. on Friday raised its annual profit forecast for a second straight quarter, as a slow recovery in non-urgent medical procedures and lower COVID-care costs help it rein in medical expenses.

AstraZeneca announced Wednesday that the results of the company’s TACKLE Phase III trial of Evusheld (tixagevimab and cilgavimab, formerly AZD7442) for the early outpatient treatment of mild-to-moderate COVID-19 have been published in The Lancet Respiratory Medicine. Results of the trial showed that Evusheld protected against progression to severe COVID-19 or death – from any cause – compared to placebo.

Pfizer Inc.’s (PFE.N) antiviral treatment Paxlovid reduces COVID-19 hospitalization and death rates in vaccinated and unvaccinated patients 65 years and older, according to a new study in Israel conducted during the rise of the Omicron variant of the coronavirus.